Cyclooxygenase-2-Derived E Prostaglandins Down-Regulate Matrix Metalloproteinase-1 Expression in Fibroblast-Like Synoviocytes via Inhibition of Extracellular Signal-Regulated Kinase Activation

Journal of Immunology

Volumn 171, Issue 11, 2003, Pages 6080-6089

  Pillinger, Michael H ^a,b,c,d   Rosenthal, Pamela B ^a,b   Tolani, Sonia N ^a,c   Apsel, Beth ^a,b   Dinsell, Victoria ^a,b   Greenberg, Jeffrey ^a,b,c   Chan, Edwin S L ^a   Gomez, Paul F ^a,b   Abramson, Steven B ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c Veterans Affairs NY Harbor Healthcare System Room 13051 C   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; COLLAGENASE 3; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROSTAGLANDIN E; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SALICYLIC ACID DERIVATIVE; SC 299; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME RELEASE; ENZYME SYNTHESIS; FIBROBLAST; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STIMULATION; SYNOVIOCYTE; UPREGULATION;

EID: 0344153852     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.11.6080     Document Type: Article

References (62)

1. Yamanishi, Y., and G. S. Firestein. 2001. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum. Dis. Clin. N. Am. 27:355.
2. Murphy, G., V. Knauper, S. Atkinson, G. Butler, W. English, M. Hutton, J. Stracke, and I. Clark. 2002. Matrix metalloproteinases in arthritic disease. Arthritis Res. 4:S39.
3. Edwards, J. C. W. 1998. The synovium. In Rheumatology, 2nd Ed. R. N. Maini, N. J. Zvaifler, J. H. Klippel, and P. A. Dieppe, eds. Mosby, London, p. 6.1.
4. Firestein, G. S. 1998. Rheumatoid synovitis and pannus. In Rheumatology, 2nd Ed. R. N. Maini, N. J. Zvaifler, J. H. Klippel, and P. A. Dieppe, eds. Mosby, London, p. 13.1.
5. Vincenti, M. P., C. I. Coon, J. A. Mengshol, S. Yocum, P. Mitchell, and C. E. Brinckerhoff. 1998. Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1). Biochem. J. 331:341.
6. Green, M. J., A. K. S. Gough, J. Devlin, J. Smith, P. Astin, D. Taylor, and P. Emery. 2003. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 42:83.
7. Cunnane, G., O. Fitzgerald, K. M Hummel, P. P. Youssef, R. E. Gay, S. Gay, and B. Bresnihan. 2001. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum. 44:1744.
8. Martel-Pelletier, J., D. J. Welsch, and J.-P. Pelletier. 2001. Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res. Clin. Rheumatol. 15:805.
9. Han, Z., D. L. Boyle, K. R. Aupperle, B. Bennett, A. M. Manning, and G. S. Firestein. 1999. Jun N-terminal kinase in rheumatoid arthritis. J. Pharmacol. Exp. Ther. 291:124.
10. Han, Z., D. L. Boyle, L. Chang, B. Bennett, M. Karin, L. Yang, A. M. Manning, and G. S. Firestein, 2001. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammation arthritis. J. Clin. Invest. 108:73.
11. Firestein, G. S., F. Echeverri, M. Yeo, N. J. Zvaifler, and D. R, Green. 1997. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arhthritis synovium. Proc. Natl. Acad. Sci. USA 94:10895.
12. Yamanishi, Y., D. L. Boyle, M. J, Pinkoski, A. Mahboubi, T, Lin, Z. Han, N. J. Zvaifler, D. R. Green, and G. S. Firestein. 2002. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am. J. Pathol. 160:123.
13. Vincenti, M. P., C. I. Coon, and C. E. Brinckerhoff. 1998. Nuclear factor κB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1β-stimulated synovial fibroblasts. Arthritis Rheum. 41:1987.
14. Yudoh, K., H. Matsuno, T. Nezuka, and T. Kimura. 1999. Different mechanisms of synovial hyperplasia in rheumatoid arthritis and pigmented villonodular synovitis: the role of telomerase activity in synovial proliferation. Arthritis Rheum. 42:669.
15. Zhang, S., J. Han, M. A Sells, J. Chernoff, U. G. Knaus, R. J. Ulevitch, and G. M. Bokoch. 1995. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J. Biol. Chem. 270:23934.
16. Wartmann, M., and R. J. Davis. 1994. The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J. Biol. Chem. 269:6695.
17. Leevers, S. J., H. F. Paterson, and C. J. Marshall. 1994. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369:411.
18. Stokoe, D., S. G. Macdonald, K. Cadwallader, M. Symons, and J. F. Hancock. 1994. Activation of raf as a result of recruitment to the plasma membrane. Science 264:1463.
19. Kyriakis, J. M., H. App, X.-F. Zhang, P. Banerjee, D. L. Brautigan, U. R. Rapp, and J. Avruch. 1992. Raf-1 activates MAP kinase-kinase. Nature 358:417.
20. Crews, C. M., and R. L. Erikson. 1992. Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product. Proc. Natl. Acad. Sci. USA 89:8205.
21. Cobb, M. H., J. R. Hepler, M. Cheng, and D. Robbins. 1994. The mitogen-activated protein kinases, ERK1 and ERK2. Semin. Cancer Biol. 5:261.
22. Pillinger, M. H., A. S. Feoktistov, C. Capodici, B. Solitar, J. Levy, T. T. Oei, and M. R. Philips, 1996. Mitogen-activated protein kinase in neutrophils and enucleate neutrophil cytoplasts: evidence for regulation of cell-cell adhesion. J. Biol. Chem. 271:12049.
23. Capodici, C., M. H. Pillinger, G. Han, M. R. Philips, and G. Weissmann. 1998. Integrin-dependent homotypic adhesion of neutrophils: arachidonic acid activates Raf-1/Mek/Erk via a 5-lipoxygenase-dependent pathway. J. Clin. Invest. 102:165.
24. Vietor, I. P., P. Schwenger, W. Li, J. Schlessinger, and J. Vilcek. 1993. Tumor necrosis factor-induced activation and increased tyrosine phosphorylation of mitogen-activated protein (MAP) kinase in human fibroblasts. J. Biol. Chem. 268:18994.
25. Schwenger, P., E. Y, Skolnik, and J. Vilcek. 1996. Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. J. Biol. Chem. 271:8089.
26. Poppers, D. M., P. Schwenger, and J. Vilcek. 2002. Persistent tumor necrosis factor signaling in normal human fibroblasts prevents the complete resynthesis of IκB-α. J. Biol. Chem. 38:29587.
27. Amin, A. R., M. G. Attur, M. Pillinger, and S. B. Abramson. 1999. The pleiotropic functions of aspirin: mechanisms of action. Cell. Mol. Life Sci. 56:305.
28. Weissmann, G. 1991. Aspirin. Sci. Am. 264(1):84.
29. Vane, J. R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231:232.
30. Amin, A. R., P. Vyas, M. Attur, J. Leszczynska-Piziak, I. R. Patel, G. Weissmann, and S. B. Abramson. 1995. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase, Proc. Natl. Acad. Sci. USA 92:7926.
31. Kopp, E., and S. Ghosh. 1994. Inhibition of NF-κB by sodium salicylate and aspirin. Science 265:956.
32. Schwenger, P., D. Alpert, E. Y. Skolnik, and J. Vilcek, 1998. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IκB α phosphorylation and degradation. Mol. Cell. Biol. 18:78.
33. Schwenger, P., P. Bellosta, I. Vietor, C. Basilico, E. Y. Skolkni, and J. Vilcek. 1997. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 94:2869.
34. Pillinger, M. H., C. Capodici, P. Rosenthal, N. Kheterpal, S, Hanft, and G. Weissmann. 1998. Modes of action of aspirin-like drugs: salicylates inhibit Erk activation and integrin-dependent homotypic adhesion of human neutrophils. Proc. Natl. Acad. Sci. USA 95:14540.
35. Georgescu, H. I., D, Mendelow, and C. H. Evans. 1988. HIG-82: an established cell line from rabbit periarticular soft tissue, which retains the "activatable" phenotype. In Vitro Cell. Dev. Biol. 24:1015.
36. Alvaro-Gracia, J. M., N. J. Zvaifler, and G. S. Firestein. 1990. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between IFN-γ and TNF-α on HLA-DR expression, proliferation, collagenase production, and GM-CSF production by rheumatoid arthritis synoviocytes. J. Clin. Invest. 86:1790.
37. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680.
38. Barchowsky, A., D. Frleta, and M. P. Vincenti. 2000. Integration of the NF-κB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 12:1469.
39. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudly, and A. R. Saitiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489.
40. Favata, M. F., K. Y. Horiuchi, E. J. Manos, A. J. Daulerio, D. A. Stradley, W. S. Feeser, D. E. Van Dyk, W. J. Pitts, R. A. Earl, F. Hobbs, et al. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273:18623.
41. Cuenda, A., J. Rouse, Y. N. Doza, R. Meier, P. Cohen, T. F. Gallagher, P. R. Young, and J. C. Lee. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:229.
42. Vincenti, M. P., and C. E. Brinckerhoff. 2002. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 4:157.
43. Warner, T. D., F. Giuliano, I. Vojnovic, A. Bukasa, J. A. Mitchell, and J. R. Vane, 1999. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA 96:7563.
44. Talley, J. J., S. R. Bertenshaw, D. L. Brown, J. S. Carter, M. J. Graneto, C. M. Koboldt, J. L. Masferrer, B. H. Norman, D. J. Rogier, Jr., B. S. Zweifel, and K. Seibert. 1999. 4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2). Med. Res. Rev. 19:199.
45. Lanzo, C. A., J. Sutin, S. Rowlinson, J. Talley, and L. J. Marnett. 2000. Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity. Biochemistry 39:6228.
46. 1 inhibits collagenase gene expression in rabbit synoviocytes and human fibroblasts. Endocrinology 131:21.
47. 1: studies in a rabbit synoviocyte cell line, HIG-82. J. Bone Miner. Res. 12:561.
48. Nagase, H., K. Suzuki, J. J. Enghild, and G. Salvesen. 1991. Stepwise activation mechanisms of the precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin). Biochim. Biophys. Acta 50:749.
49. Sun, Y., L. Wenger, C. E. Brinckerhoff, R. R. Misra, and H. S. Cheung. 2002. Basic calcium phosphate crystals induce matrix metalloproteinase-1 through the Ras/mitogen-activated protein kinase/c-Fos/AP-1/metalloproteinase 1 pathway: involvement of transcription factor binding sites AP-1 and PEA-3. J. Biol. Chem. 277:1544.
50. Menghsol, J. A., M. P. Vincenti, C. L. Coon, A. Barchowsky, and C. E. Brinckerhoff. 2000. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor κB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 43:801.
51. Cook, S. J., and F. McCormick. 1993. Inhibition by cAMP of ras-dependent activation of Raf. Science 262:1069.
52. Wu, J., P. Dent, T. Jelinek, A. Wolfman, M. J. Weber, and T. W. Sturgill. 1993. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 262:1065.
53. Dumaz, N., and R. Marais. 2003. PKA blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J. Biol. Chem. 278:29819.
54. 1 inhibits chemoattractant-induced mitogen-activated protein kinase activity in human neutrophils. In Advances in Prostaglandin, Thromboxane, and Leukotriene Reserach, Vol. 23. B. Samuelsson, ed. Raven Press, New York, p. 311.
55. Pillinger, M. H., C. Capodici, G. Han, and G. Weissmann. 1997. Inflammation and anti-inflammation: gating of cell-cell adhesion at the level of mitogen-activated protein kinases. Ann. NY Acad. Sci. 832:1.
56. Dayer, J. M., S. M. Krane, R. G. Russell, and D. R. Robinson. 1976. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc. Natl. Acad. Sci. USA 73:945.
57. He, W., J. P. Pelletier, J. Martel-Pelletier, S. Laufer, and J. A. DiBattista. 2002. Synthesis of interleukin-1β, tumor necrosis factor-α, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J. Rheum. 29:546.
58. 1 inhibit cytokine-induced metalloproteinase expression in human synovial fibroblasts. Lab. Invest. 71:270.
59. 2: mediation by protein kinase A and role of interleukin-1. Mol. Cell. Endocrinol. 103:139.
60. 1 on adjuvant arthritis. Nature 234:304.
61. 1 hybrid mice. Arthritis Rheum. 20:1449.
62. Pelletier, J.-P., J. C. Fernandes, J. Brunet, F. Moldovan, D. Schrier, C. Flory, and J. Martel-Pelletier. 2003, In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 48:1582.